Meeting
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
Authors
Aaron Philip Mitchell
Memorial Sloan Kettering Cancer Center, New York City, NY
Aaron Philip Mitchell , Akriti A. Mishra , Peter B Bach , Michael J. Morris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 68)
DOI
10.1200/JCO.2021.39.6_suppl.68
Abstract #
68
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
First Author: Michael E. Rader
Poster
2022 ASCO Genitourinary Cancers Symposium
Use of bone modifying agents for metastatic castrate-resistant prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2014 Genitourinary Cancers Symposium
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.
First Author: Matthew R. Smith
Poster
2011 ASCO Annual Meeting
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
First Author: N. D. Shore